<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524937</url>
  </required_header>
  <id_info>
    <org_study_id>P160942J</org_study_id>
    <nct_id>NCT03524937</nct_id>
  </id_info>
  <brief_title>Prevention of Delirium in Intensive Care by Melatonin</brief_title>
  <acronym>DEMEL</acronym>
  <official_title>Prevention of Delirium in Intensive Care by Melatonin: a Prospective, Multicentre, Randomized, Double Blind, Placebo, Multi-arm, Multi-stage Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, Phase 2b/3 two-part adaptive clinical
      trial. The trial is designed to investigate the pharmacokinetics and the efficacy of multiple
      dosing regimens of melatonin and to confirm the efficacy and safety of one dosing regimen in
      prevention for delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of the study is a single daily fixed-hour (21h) dose of 15 mL of an oral syrup, at
      one of the 3 following concentrations of melatonin: 0 mg/ml i.e. 0 mg/day (placebo); 0.02
      mg/ml, i.e. 0.3 mg/day (low dose of melatonin) or 0.2 mg/ml, i.e. 3 mg/day (high dose of
      melatonin). The three dosages will be identical in appearance and volume.Treatment will be
      administered up to Day-14 (or death or discharge if these occur before Day-14). Randomization
      will be stratified by center.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium incidence</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day 28 Mortality</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>At day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate number of days alive without coma nor delirium</measure>
    <time_frame>Up to day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">355</enrollment>
  <condition>Mechanically Ventilated Patients</condition>
  <arm_group>
    <arm_group_label>MELATONIN (LOW DOSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELATONIN (HIGH DOSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily administration of identical placebo up to 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MELATONIN (HIGH DOSE)</intervention_name>
    <description>Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days</description>
    <arm_group_label>MELATONIN (HIGH DOSE)</arm_group_label>
    <other_name>N-acetyl-5-methoxytryptamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MELATONIN (LOW DOSE)</intervention_name>
    <description>Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days</description>
    <arm_group_label>MELATONIN (LOW DOSE)</arm_group_label>
    <other_name>N-acetyl-5-methoxytryptamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Patient under invasive mechanical ventilation

          -  Anticipated stay in intensive care unit of at least 48 hours

          -  Informed consent signed by the patient or a relative or emergency consent

        Exclusion Criteria:

          -  Invasive mechanical ventilation for more than 48 hours

          -  known pregnancy or breastfeeding

          -  No understanding of the French language, deafness

          -  Dementia (Mini Mental State &lt;20) or known chronic psychosis

          -  Delirium (positive CAM-ICU score) before or at the time of randomization

          -  Alcohol withdrawal syndrome before or at the time of randomization with Cushman score
             ≥5

          -  Inability to use the enteral route, food intolerance with vomiting

          -  Severe hepatic insufficiency (prothrombin level &lt;30%)

          -  Ongoing treatment with melatonin or a drug that interacts or modifies its metabolism
             (fluvoxamine, 5- or 8-methoxypsoralen, estrogen, cimetidine, carbamazepine,
             rifampicin)

          -  known allergy to melatonin

          -  moribund state

          -  Patient admitted to intensive care for cardiopulmonary arrest, stroke, head trauma,
             neurosurgery.

          -  Patient not affiliated to social security

          -  Patient participating in another interventional clinical study with melatonin and / or
             for whom delirium is the primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>France GUYOT</last_name>
    <role>Study Chair</role>
    <affiliation>DRCI-Assistance Publique des Hopitaux de paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keyvan RAZAZI</last_name>
    <phone>1.49.81.23.93</phone>
    <phone_ext>33</phone_ext>
    <email>keyvan.razazi@aphp.fr</email>
  </overall_contact>
  <reference>
    <citation>Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62.</citation>
    <PMID>15082703</PMID>
  </reference>
  <reference>
    <citation>Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001 Dec 5;286(21):2703-10.</citation>
    <PMID>11730446</PMID>
  </reference>
  <reference>
    <citation>Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001 May;27(5):859-64.</citation>
    <PMID>11430542</PMID>
  </reference>
  <reference>
    <citation>Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007 Jan;33(1):66-73. Epub 2006 Nov 11.</citation>
    <PMID>17102966</PMID>
  </reference>
  <reference>
    <citation>Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001 Dec;27(12):1892-900. Epub 2001 Nov 8.</citation>
    <PMID>11797025</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Prevention</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

